FibroGen

FIBROGEN INC

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.

Konskie,,Poland,-,March,08,,2025:,Restoration,Hardware,Company,Logo

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADBE

BIAF

CGBS

EONR

FGEN

GNLN

HCTI

HUSA

INDO

NINE

PRZO

RNTX

RSLS

SBET

TPET

TRAW

USEG

VEON

RH sorprende con ganancias positivas en el primer trimestre y mantiene su guía para 2025, mientras sus acciones suben un 18,2 %.

Las acciones de RH se disparan un 18%; Aquí están 20 acciones que se mueven antes de la apertura del mercado

AdobeStockholm,,Sweden,-,July,26,,2021:,A,Wall,Sign,For

ZDGE

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este viernes: ADBE, MNY, RH, FGEN y ZDGE.

5 acciones en el foco este viernes: ADBE, MNY, RH, FGEN y ZDGE

FibroGen Inc

Earnings

Press Releases

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

Management

FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

FibroGen Announces 1-for-25 Reverse Stock Split

FibroGen to Report Second Quarter 2025 Financial Results

FibroGen Announces Positive Type C Meeting with the FDA for Roxadustat in Patients with Anemia Associated with Lower-Risk Myelodysplastic Syndromes

FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update

Contracts

FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation

FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million

Health Care

FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

Annovis Bio

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

AlphaTON Capital

Celularity

Dyadic International, Inc. - Common Stock

Dyadic International

Elutia

Equillium

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

Evaxion

Generation Bio

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Liminatus Pharma, Inc. - Class A Common Stock

Liminatus Pharma

Lantern Pharma

LAVA Therapeutics

Medicus Pharma

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

Q32 Bio

RenovoRx

Senti Biosciences

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

Xilio Therapeutics

XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock

Comments

FibroGen

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL